Comprehensive Fexlast™ Overview

Fexlast™ is a clinically indicated, dual-action prescription formulation designed to provide robust, multi-symptom relief from allergic rhinitis and comorbid asthma. By combining a non-sedating, long-acting second-generation antihistamine with a potent leukotriene receptor antagonist, Fexlast™ addresses both the immediate histamine-driven allergic responses and the delayed inflammatory pathways that affect the respiratory tract.

Each film-coated tablet delivers:

• Fexofenadine Hydrochloride IP: 120 mg
• Montelukast Sodium IP: Equivalent to Montelukast 10 mg

Manufactured for FENESTRA PHARMACEUTICALS, Fexlast™ is produced in advanced, state-of-the-art facilities complying with strict Schedule H and Good Manufacturing Practice (GMP) standards to ensure optimal purity, uniformity, and clinical potency.

Key Features & Therapeutic Benefits

• Dual Mechanism Synergism: Simultaneously blocks H1 histamine receptors and cysteinyl leukotriene (CysLT1) receptors, tackling airway inflammation, tissue edema, mucosal secretion, and bronchoconstriction from two distinct pharmacological angles.
• Non-Sedating 24-Hour Allergy Control: Fexofenadine delivers rapid, peripheral H1-antagonism to relieve sneezing, itching, watery eyes, and runny nose without crossing the blood-brain barrier, preventing daytime drowsiness.
• Targeted Airway Anti-inflammatory Action: Montelukast effectively mitigates airway smooth muscle constriction and eosinophil-induced inflammation, keeping bronchial and nasal passages clear.
• Clinically Indicated For: Chronic or seasonal allergic rhinitis, perennial allergic rhinitis, and the prevention of accompanying asthmatic symptoms or exercise-induced bronchoconstriction.

Scientific & Clinical Rationale

• Fexofenadine Hydrochloride: Extensive global clinical documentation confirms its high efficacy profile and lack of cardiotoxic or sedative side effects compared to older antihistamines. It provides rapid symptom relief that lasts for a full 24 hours.
• Montelukast Sodium: Validated by multiple large-scale clinical trials as a foundational non-steroidal controller for chronic asthma and allergic rhinitis, significantly reducing airway hyperresponsiveness and reliance on rescue inhalers.
• Combination Efficacy: Published clinical studies show that co-administration of an antihistamine and a leukotriene receptor antagonist achieves superior control of nasal congestion and lower airway reactivity than either monotherapy alone.

Directions for Use & Safety Guidelines

• Recommended Dose: 1 tablet per day, or as explicitly directed by a Registered Medical Practitioner.
• Administration: Swallow the tablet whole with a glass of water. It can be taken with or without food. Avoid taking it with fruit juices (such as grapefruit, orange, or apple) as they may reduce the absorption of fexofenadine.
• Storage: Store protected from light and moisture, at a temperature not exceeding 30°C. Keep out of reach of children.
• Warning: This is a prescription medication. Do not exceed the recommended dose. Patients with pre-existing renal impairment or a history of neuropsychiatric events should consult their physician before use.

FAQs – Frequently Asked Questions

What is Fexlast™ used for?

Fexlast™ is clinically formulated to manage symptoms of seasonal and perennial allergic rhinitis (such as runny nose, sneezing, itchy or watery eyes, and nasal congestion) while simultaneously preventing and controlling associated airway inflammation or allergic asthma.

Are the ingredients in Fexlast™ scientifically validated?

Yes. Both Fexofenadine and Montelukast are globally recognized, well-established therapeutic agents extensively backed by clinical trials confirming their safety and synergistic efficacy in managing upper and lower respiratory allergic diseases.

Is Fexlast™ a prescription drug?

Yes, Fexlast™ is a Schedule H Prescription Drug. In accordance with statutory warnings, it cannot be sold by retail without a valid prescription from a Registered Medical Practitioner.

Does Fexlast™ cause drowsiness?

Fexofenadine is a second-generation, non-sedating antihistamine that does not readily enter the central nervous system. While drowsiness is highly uncommon, individual responses can vary; avoid operating heavy machinery or driving if you experience unexpected dizziness.

Regulatory Compliance & Trust

• Schedule H Prescription Status: CAUTION: Not to be sold by retail without the prescription of a Registered Medical Practitioner. To be taken strictly under medical supervision.
• Quality Assurance & Manufacturing: Marketed by Fenestra Pharmaceuticals Pvt Ltd and manufactured under rigorous quality control standards (including rigorous dissolution, assay, and purity testing) to guarantee batch-to-batch bioequivalence and chemical stability.
• Full Batch Traceability: Every box carries verified regulatory markings, licensing specifications, and distinct batch identifiers (e.g., Batch No: ACV04ADA) ensuring absolute transparency from manufacturing facility to patient care.

Contact & Support

For clinical information, partnership, or compliance queries, reach our supplement specialists contact page.